
Opinion|Videos|September 17, 2024
Management of Oral Toxcities associated with GPRC5D Bispecifics Nail
Author(s)Larysa Sanchez, MD, Samantha Shenoy, MSN, NP
Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What are some adverse events (AEs) observed with talquetamab and how are these managed?
- Please discuss management of oral toxicities.
- Please discuss management of skin and nail AEs.
Advertisement
Related to this article

Discover how equine-assisted services support patients with cancer by improving emotional wellness, building confidence, and enhancing quality of life.

Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.

ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.

A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.

Life table analysis estimates residual ovarian cancer risk by current age and planned age at risk-reducing surgery.

Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS efficacy data.

FDA-approved subcutaneous isatuximab via on-body injector changes myeloma care workflows. Experts outline what nurses and PAs need to know.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
2
Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk
3
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive NMIBC
4
Anktiva for Papillary NMIBC: What Nurses Need to Know About the Regimen
5

